Investing Port

P/S	435.81
P/BV	16.41
EV/EBITDA	-19.23
Цена ао	64.28

Institutions	Объем	Доля, %
AIG Asset Management (U.S), LLC	5576380	4.54
Aisling Capital Management LP	3989412	3.25
Kohlberg Kravis Roberts & Co LP	34510971	28.13
SC US (TTGP), LTD.	2544738	2.08
BlackRock Fund Advisors	8099277	6.6
Perceptive Advisors LLC	6706268	5.46
Viking Global Investors LP	26620991	21.69
Cormorant Asset Management, LLC	2265762	1.85
Nicholas Investment Partners	24745	0.02
Pacific Life Fund Advisors LLC (PLFA)	159277	0.13
Fernwood Investment Management, LLC	143835	0.12
CT Mason	73425	0.06
Janus Capital Management LLC	1840285	1.5
Defiance ETFs, LLC	4435	0
Bayview Asset Management Co., Ltd.	35200	0.03
Ohio National Investments Inc	73494	0.06
Baillie Gifford Investment Management (Europe) Limited	23314	0.02
Northern Trust Investments Inc	1346837	1.1
Hillhouse Capital Advisors, Ltd.	4711604	3.84
Rockefeller & Co. LLC	117235	0.1
WCM Investment Management, LLC	6378	0.01
UBS Asset Management (Americas) Inc	32157	0.03
Kohlberg Kravis Roberts & Co LP	34510971	28.12
Donoghue Forlines LLC	24712	0.02
BAMCO Inc	25876	0.02
AMG Funds LLC	179505	0.15
American Century Investment Management, Inc	657864	0.54
Nicholas Investment Partners LP	32979	0.03
SSGA Funds Management Inc	2900278	2.36

ETF	Доля, %	Доходность за год, %
Defiance Nasdaq Junior Biotechnology ETF	3.09

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license agreements with the Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc.; strategic collaboration agreements with Johns Hopkins University and University of Florida; collaboration with University of Colorado Anschutz Medical Campus to advance novel research on genetically driven diseases into therapeutic applications for patients; and collaboration with Salk Institute for Biological Studies. The company was founded in 2015 and is headquartered in Palo Alto, California.